Introduction to Cellular cgmp
|
|
- Neal Lane
- 7 years ago
- Views:
Transcription
1 Introduction to Cellular cgmp Yen-Michael S. Hsu, MD, PhD, FCAP Assistant Professor of Pathology and Laboratory Medicine Assistant Director of Transfusion Medicine Assistant Director of Cellular Therapies Weill Cornell Medical College
2 Overview of Presentation What is current good manufacturing practice (cgmp)? Rules: regulations & accreditations How to stay compliant? Facility design & operation How to start an clinical trial with novel cell product? Summary 2
3 GMP World Wide Republic of China USA European Union India Japan Canada Taiwan 3
4 CAR-T on Magazine Cover 4
5 Examples of Novel Cellular Product under cgmp Manufacturing CAR-T» CD19 (ALL, CLL, MM, MCL)» Her2 (Glioblastoma, sarcoma)» CD30 (NHL)» CD22 (resistant/refractory ALL) CAR-NK» GD2 (Neuroblastoma) Allogeneic anti-viral Lymphocytes» AdV, EBV, CMV Hematopoietic Stem Cell Expansion» Cord blood» CD34-selected HSC» Small molecules/chemical 5
6 Why is cgmp Needed? 6
7 Origin & Purpose of cgmp 1938 Federal Food, Drug and Cosmetic Act Establish the minimum requirement» Drug preparation for human» Animal consumption Safety, Purity, Potency, Identity, and Stability OR 7
8 cgmp = Clean Room? 8
9 cgmp = A highly regulated system of practices by FDA 9
10 cgtp vs. cgmp in Cellular Therapy cgxp cgtp cgmp Purpose/Core requirements Prevent introduction/transmission/spread of communicable diseases Tractability & traceability Can manufacture HCT/P under Section 361 of the PHS Act Drug manufacturing standard Purity/Potency/Safety/Identify/Stability cgtp + DETAILED documentations Regulated under Section 351 of the PHS Act 10
11 351 vs. 361 Product Manufacturing Human Cells, Tissue, Tissues-based Product (HCT/P) AKA: 361 product Established in May 2005 Exempted from cgmp regulations ( 351 products) Examples Bone, ligament, skin, dura mater, heart valve, cornea Excluding Vascularized transplantable organ Whole blood & blood component Secreted or extracted product 11
12 361 Product Criteria 1. Minimal manipulation 2. Homologous use 3. No combination with cells or tissues 4. No systemic effect nor dependent on metabolic activity of living cells 12
13 Critical cgmp Elements Training & certification Processing control (SOP) Production control Equipment Facility Environmental monitoring Validation Management (QC/QA) DOCUMENTATION! 13
14 Regulatory Agencies for Biologics
15 Federal Agencies FDA (Food and Drug Administration) Public Health Service Act (initially to regulate biological products) Food, Drug, and Cosmetic Act (to regulate food, drug, and medical devices) Title 21 of Code of Federal Regulations (CFR) CBER (Center for Biologics Evaluation and Research) OCTGT (Office for Cellular, Tissue and Gene Therapies) Regulates HCT/Ps under sections 351 & 361 CDRH (Center for Devices and Radiological Health) CDER (Center for Drug Evaluation and Research) Monoclonal antibodies, therapeutic molecules (protein, cytokine, hormone, etc.) for in vivo functions 15
16 Clinical Laboratories Regulations State Regulations CLIA 88 16
17 Be Familiar with Laws & Regulations 21 CFR 211 s: cgmp 21 CFR 312: IND 21 CFR 600 s: Biologics 17
18 Cellular Therapy Accreditations AABB FACT 18
19 Systems Needed to Stay Legal Quality Assurance!
20 Risk-based QA Philosophy & Intent ASTM E Risk based and science based approach Specification/design/verification of systems and equipment Provide capability to support consistent manufacturing that meets defined quality requirements. Subject Matter Experts (SMEs) Critical aspects of manufacturing systems to drive specification, design, and verification of facilities and equipment. 20
21 Scope of Quality Assurance Development requirement Specification Verification Acceptance/release Continuous improvement 21
22 Building a cgmp Facility
23 Facility Designs: Rule of Thumb Space & work flow to prevent mix-up Task and operation specific zone Facilitate cleaning, operation and maintenance Air flows from more clean to less clean User/Project specific requirements 23
24 cgmp Clean Room Space HVAC (HEPA filter) Lighting High purity gases Equipment Building management Cleanable surface Security system 24
25 ISO Classifications & Maintenance Class/(ISO Rating) Example of operation Class 100/ ISO 5 open manipulations (Biological Safety Cabinet) Aseptic operation Class 1000/ ISO 6 Class 10,000/ISO 7 Adjacent to Class 100 Equipment (centrifuge, incubator, close-systems) Class 100,000/ ISO 8 Surround Class 10,000 (moderate monitor/control) Equipment Material storage Prevent contamination & cross-contamination Reduce airborne and waterborne particles No street clothes (gowning) No sink (alcohol wipe) Segregation of materials and processes with tracking Aseptic techniques 25
26 Considerations During Designs Multidisciplinary or isolated? Starting material handling Control system Automation Open vs. close systems Product change-over Construction Staff operation Maintenance Safety Environmental issues Licensure or only IND 26
27 Facility Design Planning Facility programming/analysis (Feasibility study) Understanding and identifying problems Quantifying needs with summary Facility team/building department: building code Synthesis/design evaluation (Feasibility study) Developing solutions for problems Implementation (based on analysis and synthesis results) Action to deliver the solutions 27
28 Client/User Specifications Product type and specifications Stage of manufacturing Scale of manufacturing Material and personnel flows Efficiency and less error prone Researcher cgmp Director Open dialogues among all participants for goals and needs 28
29 Facility Design Flexibility Vs. Clean Room Advantage Disadvantage Modular Clean Space Lower cost Easier cleaning Easier monitoring Difficulty to scale up Less flexible to adapt protocol changes
30 Manufacturing Manufacturing SOPs Automations Product Change-over procedure 30
31 Cost & Schedule Realistic cost control phase) Interact to avoid duplication and stimulate comparison Difficult to assess or project. Often based on historical cost data. Likely a moving target! 31
32 Pitfalls to Avoid During Planning Phase Lack of commitment to process Open to ideas and understanding of day-to-day operational issues Preconceived solutions Brainstorming, not brainwashing Fostering creativity and insights Narrow focus Unreasonable schedule Allow more time and expense Too much details 32
33 Facility Validation Validation master plan (did I remember everything?) User requirement specification Design qualification (will I be ok to start?) IQ/OQ/PQ Maintenance qualification (is everything taken cared?) 33
34 Facility Operation: Ready for FDA Inspection & Studies ALL cgmp components reviewed and validated Stay updated on FDA regulation changes Compliance of corrective/preventive actions Avoid unnecessary practice changes during peri-inspection period 34
35 Designing Clinical Trials Using Investigational Cellular Therapy Products Exciting but many cautions ahead
36
37 Phases of Clinical Trials Phase Purposes/Goals # participations Phase 0 Pharmacodynamics Pharmacokinetics ~10 Phase I Safety Phase II Efficacy Phase III Comparison Phase IV Post-Marketing Study dependent 37
38 Investigational New Drug (IND) Regulatory pathway to conduct a clinical trial using a cell therapy (CT) product HCT/P not regulated under 21 CFR (Section 361 of PHS Act) Sponsor: Responsible for and initiate clinical investigation Investigator: Conducting and directing clinical trials and product administration Subject safety is Priority 38
39 Pre-IND Preparation/Meeting MOST CRITICAL! Pre-clinical testing Cell product manufacturing Cell product characterization Sponsor questions for FDA 39
40 Starting The IND Process Fulfill pre-ind meeting FDA response time: 30 days Complete Chemistry Manufacturing Control (CMC) Identification, safety, purity, and quality of product Variable depends the phase of the study Generating meaningful data for phase III study 40
41 Many Guidance Documents Available 41
42 Summary Patient safety should NEVER be compromised! Co-evolution of science & manufacturing. Sliding scale approach to meet cgmp requirements Endpoint testing alone Assure a quality product Facility design to meet current and future needs Reach the HIGHEST level & standard possible 42
43 References Adrian Gee. Cell Therapy cgmp Facilities and Manufacturing. New York, NY:Springer New York Dordrecht Heidelberg London, CFR Mini-Handbook. AABB Edition. Cellular & Gene Therapy Guidances tion/guidances/cellularandgenetherapy/ 43
US Regulations for Import and Export of Cell Therapy Products
US Regulations for Import and Export of Cell Therapy Products Kurt Gunter, MD U Minnesota UCB Transplants (2001-2007)* Total units: 790 Number US banks: 19 Number non-us banks: 12 % units from non-us banks:
More informationcgmp Challenges for Cord Blood Banks
cgmp Challenges for Cord Blood Banks Donna M. Regan, MT(ASCP)SBB St. Louis Cord Blood Bank @ SSM Cardinal Glennon Children s s Medical Center Cord Blood Bank processing facility challenges What does cgmp
More information[DOCKET NO.96N-0002] DRAFT
[DOCKET NO.96N-0002] DRAFT DRAFT DOCUMENT CONCERNING THE REGULATION OF PLACENTAL/UMBILICAL CORD BLOOD STEM CELL PRODUCTS INTENDED FOR TRANSPLANTATION OR FURTHER MANUFACTURE INTO INJECTABLE PRODUCTS DECEMBER,
More informationCombination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma
Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)
More informationLicensing Your Cord Blood
Licensing Your Cord Blood A Guide to Getting FDA Approval for Marketing your Public Bank s Lifesaving Product as a Prescription Drug 1.888.MEDIWARE Mediware.com Contents Introduction 1 Profits for Today,
More informationCord Blood Banking and Biologic License Application (BLA) November 19, 2010
Cord Blood Banking and Biologic License Application (BLA) November 19, 2010 1 Webinar Presenters Tara Sadeghi, BS University of Texas MD Anderson Cord Blood Bank Michele Carbone, MS, CLS, MT(ASCP)SH,DLM,CQM,
More informationGuidance for Industry
Guidance for Industry Minimally Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution in Patients with Hematological Malignancies DRAFT GUIDANCE This
More informationDesign, Operation and Management of GTP/GMP Cell Engineering Facilities
Design, Operation and Management of GTP/GMP Cell Engineering Facilities Scott R. Burger, MD Advanced Cell & Gene Therapy BFDA 2007 International Symposium on Regulation of Human Cell and Tissue- Based
More informationHematopoietic stem and progenitor cell transplants: regulation and accreditation
Pediatr Transplantation 2003: 7 (Suppl. 3): 101 108 Printed in UK. All rights reserved Copyright Ó 2003 Blackwell Munksgaard Pediatric Transplantation ISSN 1398-2265 Hematopoietic stem and progenitor cell
More informationCord Blood Licensure. Session 2C: Advanced Cell Therapies April 11, 2013
Cord Blood Licensure Session 2C: Advanced Cell Therapies April 11, 2013 Objectives Describe rationale for cord blood licensure Cite licensure regulations Illustrate a case study of one program s pathway
More informationPreparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationCMC Writing for IND Applications. David H. McKenna, Jr., M.D. University of Minnesota April 10-11, 2007 Workshop
CMC Writing for IND Applications David H. McKenna, Jr., M.D. University of Minnesota April 10-11, 2007 Workshop CMC Writing for IND Applications ~Outline~ What is the CMC section? Who writes the CMC section?
More informationManufacturing Cellular Products for International Clinical Trials
Manufacturing Cellular Products for International Clinical Trials Q U A L I T Y A N D O P E R A T I O N S T R A C K 7 4 / 2 5 / 1 4 1 3 : 4 5-1 5 : 1 5 Olive J Sturtevant, MHP,MT (ASCP)SBB, CQA Director
More informationGuidance for Industry
Guidance for Industry Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationGuidance for Industry
Guidance for Industry Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications Additional copies of this guidance are
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationStem Cell-based Therapies and FDA Regulations
Stem Cell-based Therapies and FDA Regulations By Trina Slabiak, MS, RAC Stem cell-based therapies are arriving in the clinic as Phase 1 studies. Which technological challenges and US Food and Drug Administration
More informationDiane Kadidlo MT(ASCP) SBB University of Minnesota Joanna Stanson, M.S. University of Pittsburgh
Production Records & Documentation Diane Kadidlo MT(ASCP) SBB University of Minnesota Joanna Stanson, M.S. University of Pittsburgh Production Records This Session: Production Records Basic Elements Regulatory
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationChallenges in the Regulation of Pediatric Clinical Trials
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
More informationCanadian Regulations Safety of Human Cells, Tissues and Organs (CTO) for Transplantation
Canadian Regulations Safety of Human Cells, Tissues and Organs (CTO) for Transplantation Presentation to the American Association of Tissue Banks Savannah, Georgia March 2008 Health Canada Update Marianne
More informationHematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low
Upstate Cord Blood Bank Hematopoietic Progenitor Cells Hematopoiesis i starts from self renewing HPC HPC differentiates t to sequentially more mature blood cells HPC circulate in very low numbers in adults
More informationBIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
More informationBiosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry DRAFT GUIDANCE This guidance document is being
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationA FDA Perspective on Nanomedicine Current Initiatives in the US
A FDA Perspective on Nanomedicine Current Initiatives in the US Carlos Peña, PhD Office of the Commissioner FDA September 3, 2010 Outline Context Nanotechnology Task Force report summary Identification
More informationEngineering Nanomedical Systems
BME 695 November 8, 2011 Engineering Nanomedical Systems Lecture 15 GMP and issues of quality control manufacture of nanodelivery systems James F. Leary, Ph.D. SVM Endowed Professor of Nanomedicine Professor
More informationRare Diseases: Common Issues in Drug Development Guidance for Industry
Rare Diseases: Common Issues in Drug Development Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationLibrary Guide: Pharmaceutical GMPs
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
More informationRegulatory Submission: Applying GLP in Surgical Efficacy Studies
Regulatory Submission: Applying GLP in Surgical Efficacy Studies Curtis Schondelmeyer, DVM Director Preclinical Veterinary Services and Efficacy and Surgical Research Services Welcome to Toxikon 2 CONFIDENTIAL
More information15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com. April 17, 2015.
15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com April 17, 2015 Dear Shareholder, We are experiencing exciting times at HemaCare. Over the course of
More informationBiobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC
Biobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC ISCT Conference, New Zealand, April 2013 April 1 st 2013 NIBSC will become part of the Medicines and
More informationFormal FDA Meeting Request: Guidance and Template
Formal FDA Meeting Request: Guidance and Template ICTR Navigators July 23, 2011 Version 2.0 Page 1 of 20 1.0 Table of Contents Section Page 1.0 Table of Contents 2 2.0 Abbreviations 2 3.0 FDA Regulations
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationGuidance for Industry
Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products Center for
More informationCreating a cgmp Facility for Early Clinical Trials of Molecular Imaging and Therapeutic Agents
Designing for the Frontiers of Research Creating a cgmp Facility for Early Clinical Trials of Molecular Imaging and Therapeutic Agents Richard J. Mohr What if it were possible to treat a cancer patient
More informationUnique Device Identification System: Small Entity Compliance Guide Guidance for Industry and Food and Drug Administration Staff
Unique Device Identification System: Small Entity Compliance Guide Guidance for Industry and Food and Drug Administration Staff Document issued on August 13, 2014 On November 5, 2014 this document was
More informationHemaCare Corporation Company Overview. Comprehensive Product and Service Solutions for BioResearch and Cellular Therapy
HemaCare Corporation Company Overview Comprehensive Product and Service Solutions for BioResearch and Cellular Therapy 2015 HemaCare Corporation Leading provider of apheresis products, human blood cells,
More informationRegulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationGuidance for Industry and FDA Staff
Guidance for Industry and FDA Staff Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution
More information2014 Annual Report on Inspections of Establishments
2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered
More informationUniversity of Colorado Hospital Policy and Procedure Transplant and Implant Tissue Storage and Issuance
University of Colorado Hospital Policy and Procedure Transplant and Implant Tissue Storage and Issuance Related Policies and Procedures: Temperature Controlled Storage Unit Monitoring Hospital Infection
More informationSummary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status
of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Shelley Grant Branch Chief, Blood Stem Cell Transplantation Program September 11, 2015 Overview December 20, 2005 - HRSA began
More informationRegulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials
Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace
More information5th Edition NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration. Summary of Changes
5th Edition NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration Summary of Changes This document summarizes the changes made to the 5th edition of the
More informationComparability of Cord Blood Units
Comparability of Cord Blood Units John D. McMannis,, Ph.D. Professor of Cancer Medicine Director, Cell Therapy Laboratory Technical Director, UT MDAnderson Cord Blood Bank Liaison Meeting, Bethesda June
More informationFAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationDo you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma
1 Who is the most influential figure in cord blood around the world? What is the biggest challenge to overcome in the use of cord blood as a source of stem cells? We asked 10 leading experts in the cord
More informationFood and Drug Administration
Center for Drug Evaluation and Research (CDER) Small Business Assistance Program The Information Source for Regulated Domestic and International Small Pharmaceutical Business CAPT Brenda Stodart, USPHS
More informationSepax. your child s cord blood is in safe hands. World leader in adult stem cell processing
Sepax your child s cord blood is in safe hands World leader in adult stem cell processing Biosafe Experience Credibility Innovation Dear Customer, Innovation in cell processing is our credo and this is
More informationUC Davis Institute for Regenerative Cures A facility supported by the California Institute for Regenerative Medicine
UC Davis Institute for Regenerative Cures A facility supported by the California Institute for Regenerative Medicine Naming Opportunities Opportunity No. Description/Features Gift Amount Institute for
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationParticle Monitoring Requirements in Pharmaceutical Cleanrooms
Particle Monitoring Requirements in Pharmaceutical Cleanrooms All drugs must be manufactured in accordance with the current Good Manufacturing Practice (cgmp) regulations. Pharmaceutical manufacturers
More informationStem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine
Stem Cells and Inner Ear Cell Regeneration Stefan Heller Stanford University School of Medicine Embryonic stem cells Induced pluripotent stem cells Somatic stem cells 50 µm Derived from the inner cell
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationWorkflow System for Paperless Air Monitoring Powered by MODA. Presented by
Introducing Hach s MET ONE Compliance Workflow System for Paperless Air Monitoring Powered by MODA Presented by Scott Hjelmervik Bob Toal Systems Director Vice President Hach Company MODA Technology Partners
More informationVoluntary Genomic Data Submissions at the U.S. FDA
Voluntary Genomic Data Submissions at the U.S. FDA International Conference on Harmonization Chicago, IL November 9-10, 9 2005 Felix W. Frueh, PhD Associate Director for Genomics Office of Clinical Pharmacology
More informationBreakthrough Therapy Program U.S. Food and Drug Administration (FDA)
Breakthrough Therapy Program U.S. Food and Drug Administration (FDA) Presentation before the European Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP) Jarilyn Dupont,
More informationTransmedcon 2014. Ahmedabad, Gujarat November 14-16, 2014
FACT Accreditation for Cord Blood Banks and Cellular Therapy Nadim Mahmud, MD, PhD Associate Professor of Medicine Division of Hematology/Oncology Director, Hospital Stem Cell Laboratory Blood & Marrow
More informationPost-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
More informationCHAPTER 7 QUALITY ASSESSMENT
CHAPTER 7 QUALITY ASSESSMENT Chapter 7 QUALITY ASSESSMENT 7.1 OVERVIEW OF CBB-SPECIFIC QUALITY ASSURANCE/QUALITY CONTROL PROGRAM An extensive, site-specific Quality Assurance/Quality Control (QA/QC) program
More informationinformation for payers and referrers
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in
More information»medical programs and services. transfusion medicine fellowship program
»medical programs and services transfusion medicine fellowship program new york blood center transfusion medicine fellowship program» Experience at one of the largest nonprofit, community-based blood centers
More informationResponse to Public Comments for the 7 th edition of Standards for Cellular Therapy Services
Please note that public comments that were submitted address the proposed Standards. The changes are best understood when the proposed Standards is compared to the final published version. The program
More informationGuidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application
Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationGLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process
More informationDISCUSSION TOOL PRESENTED TO THE AABB CT REGULATORY AFFAIRS SUBSECTION
1 US FDA Form 483: A Case Study DISCUSSION TOOL PRESENTED TO THE AABB CT REGULATORY AFFAIRS SUBSECTION DEVELOPED BY FRAN RABE 2 Introduction This case study is intended to extract portions of information
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationCell Bank Safety Testing for Cellular Therapeutics. Christopher A Bravery
Cell Bank Safety Testing for Cellular Therapeutics Christopher A Bravery cbravery@advbiols.com 1 Introduction Definitions used in this talk Cellular therapeutics (CTP) EU: Advanced Therapy Medicinal Products
More informationHippocrates, Cords and Quality
Hippocrates, Cords and Quality Transfusion Medicine Resident Education Seminar April 3,2012 Renee Naiman, Director, Quality and Regulatory Affairs Overview -Brief update of cord blood history and usage.
More informationGuidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
More information4. Cell Separation - Clinical Research Products
4. Cell Separation - Clinical Research Products Introduction of Dynabeads ClinExVivo 53 Dynabeads ClinExVivo Epoxy 54 Dynabeads ClinExVivo Sheep anti-mouse IgG 55 Visit for the latest product up-dates
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationStem Cells Market Trends based on Primary Industry Analysis
GENReports: Market & Tech Analysis Stem Cells Market Trends based on Primary Industry Analysis > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us > Gary Oosta,
More informationUnderstanding USP 797
DDK Scientific, Corp. Raul Duarte June 2008 Copyright DDK Scientific, Corp. 2008, 2009 DDK Scientific, Corp. Proprietary The purpose of USP 797 is to prevent harm and fatality to patients that could result
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
More informationINTRODUCTION. This book offers a systematic, ten-step approach, from the decision to validate to
INTRODUCTION This book offers a systematic, ten-step approach, from the decision to validate to the assessment of the validation outcome, for validating configurable off-the-shelf (COTS) computer software
More informationProviding Regulatory Submissions In Electronic Format Standardized Study Data
Providing Regulatory Submissions In Electronic Format Standardized Study Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationMedical Device Training Program 2015
Medical Device Training Introduction Supplementary training and education is often overlooked by medical device professionals until it is triggered by an upcoming FDA or Notified Body and/or ISO 13485
More informationDevelopment and Validation of In Vitro Diagnostic Tests. YC Lee, Ph.D. CEO
Development and Validation of In Vitro Diagnostic Tests YC Lee, Ph.D. CEO 1 Validation of In Vitro Diagnostic Tests Validated d Diagnostic Test should: Provides test results that identify if positive i
More informationRisk-Based Environmental Monitoring. Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI
Risk-Based Environmental Monitoring Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI Presenter Marsha Stabler Hardiman Over 20 years experience in the
More informationQuality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion
Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS Eli Lilly & Co. Principal Consultant - Regulatory PDA/FDA Joint September 20 th, 2011
More informationClinical trials for medical devices: FDA and the IDE process
Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,
More informationFAILURE INVESTIGATION AND ROOT CAUSE ANALYSIS
FAILURE INVESTIGATION AND ROOT CAUSE ANALYSIS Presented By Clay Anselmo, R.A.C. President and C.O.O. Reglera L.L.C. Denver, CO Learning Objectives Understand the Definitions of Failure Investigation and
More informationOverview of Pre-Approval Inspections
Overview of Pre-Approval Inspections Presented by: Kelli F. Dobilas NWJ-DO Pre-Approval Manager Pre-Approval Drug Inspections What are Pre-Approval Inspections? One of the last reviews of the drug approval
More informationDr.ssa Maria Luisa Nolli CEO
IL RUOLO DELLE PICCOLE E MEDIE INDUSTRIE NELLA PROMOZIONE DELLA MEDICINA TRASLAZIONALE Quality and Innovation Dr.ssa Maria Luisa Nolli CEO INTRODUCTION ARETA INTERNATIONAL 12 years of experience in contract
More informationExtemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationPACT Web Seminar July 19, 2007
PACT Web Seminar July 19, 2007 Phyllis I. Warkentin, MD Professor, Pathology and Pediatrics University of NE Medical Center Medical Director Chairman, Accreditation Program Foundation for the Accreditation
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More informationDocument Review: Centers for Medicare and Medical Service (CMS) What Do I Need to Do to Assess Personnel Competency?
Document Review: Centers for Medicare and Medical Service (CMS) What Do I Need to Do to Assess Personnel Competency? http://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/clia_compbrochure_508.pdf
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationRegulations Concerning
Regulations Concerning Airborne Particle Counting Two types of activities performed with an airborne particle counter: Classification focuses primarily on the environment Particle Counting Applications
More information[Indian Stem Cell Banking Market: Trends & Opportunities (2012-2017)]
[Indian Stem Cell Banking Market: Trends & Opportunities (2012-2017)] Executive Summary Stem Cells have a remarkable ability to develop in various body cells of a human. These occur in the earliest stages
More informationImporting pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
More informationORACLE CONSULTING GROUP
ORACLE CONSULTING GROUP An Official United States Agent Firm for Foreign Establishments CONSULTING MEMORANDUM: DEALING WITH A MEDICAL DEVICE IN THE U.S. 5398 Golder Ranch Rd., Ste. 1 Tucson, Arizona 85739
More information